Endocrine Abstracts

The human somatostatin receptor 3 (hsst3) is expressed in about 50% of all neuroendocrine tumours. The sst3 receptor is unique among somatostatin receptors which can initiate apoptosis of tumour cells through activation of the tumour suppressor p53. Furthermore, treatment of the sst3 receptor with somatostatin or stable somatostatin analogues such as octreotide or pasireotide can inhibited tumour cell proliferation. However, at present little is known about the agonist-induced...